USOO9234204B2

(12) United States Patent (10) Patent No.: US 9.234,204 B2 Qvit-Raz et al. (45) Date of Patent: *Jan. 12, 2016

(54) TOPICAL COMPOSITION COMPRISING FOREIGN PATENT DOCUMENTS TRANSFORMED BACTERIA EXPRESSINGA COMPOUND OF INTEREST EP O975227 B1 2, 2000 EP 1322318 B1 T 2003 EP 1473028 A1 11, 2004 (71) Applicant: TopGenix, Inc., Menlo Park, CA (US) EP 1789.529 A1 5/2007 EP 2364712 B1 9, 2011 (72) Inventors: Noga Qvit-Raz, Menlo Park, CA (US); FR 28032O1 A1 T 2001 Tahel Altman, Menlo Park, CA (US) WO WO86,02350 A1 4f1986 WO WO 89,01970 A2 3, 1989 WO WO96, 11277 A1 4f1996 (73) Assignee: TopgeniX, Inc., Menlo Park, CA (US) WO WOO2A28402 A1 4/2002 WO WOO2,39974 A1 5, 2002 (*) Notice: Subject to any disclaimer, the term of this WO WOO3,O2O236 A2 3, 2003 patent is extended or adjusted under 35 WO WO 2006/013441 A2 2, 2006 U.S.C. 154(b) by 0 days. WO WO 2007/039086 A1 4/2007 WO WO 2011/15O127 A2 12/2011 This patent is Subject to a terminal dis WO WO 2011, 151426 A2 12/2011 claimer. WO WO 2012/150269 A1 11/2012 WO WO 2013/044059 A2 3, 2013 (21) Appl. No.: 13/961,845 OTHER PUBLICATIONS (22) Filed: Aug. 7, 2013 Shicket al., “Mycosporine-Like Amino Acids and Related Gadusols: Biosynthesis, Accumulation, and UV-Protective Functions in (65) Prior Publication Data Aquatic Organisms' 64 Annual Review of Physiology 223-262 US 2014/0044653 A1 Feb. 13, 2014 (2002).* Baskus et al., “The Genetic and Molecular Basis for Sunscreen Biosynthesis in Cyanobacteria' 329 Science 1653-1656 (with Sup Related U.S. Application Data porting Online Material) (2010).* Rastogi et al., “Photoprotective compounds from marine organisms' (60) Provisional application No. 61/836,594, filed on Jun. 37 Journal of Industrial Microbiology and Biotechnology 537-558 18, 2013, provisional application No. 61/680,620, (2010).* filed on Aug. 7, 2012. Gao et al., “Microbial ultraviolet Sunscreens' 9 Nature Reviews Microbiology 791-802 (Nov. 2011).* (51) Int. Cl. Hentges, “The Anaerobic Microflora of the Human Body” 16(Suppl. A6 IK 8/18 (2006.01) 4) Clinical Infectious Diseases S175-S180 (1993).* CI2N 15/74 (2006.01) Pouwels et al., “Genetics of lactobacilli: plasmids and gene expres A61O 1704 (2006.01) sion” (64 Antonie van Leewenhoek 85-107 (1993).* A61O 1700 (2006.01) Perez-Arellano et al., “Construction of Compatible Wide-Host A 6LX8/99 (2006.01) Range Shuttle Vectors for Lactic Acid Bacteria and Escherichia coli A61O 19/00 (2006.01) 46 Plasmid 106-116 (2001).* A61O 19/08 (2006.01) Sanchez et al., “General and specialized vectors derived from A6 IK35/744 (2015.01) pBM02, a new rolling circle replicating plasmid of Lactococcus CI2N I/2O (2006.01) lactis” 51 Plasmid 265-271 (2004).* CI2P 21/04 (2006.01) Kleerebezem et al., “Controlled Gene Expression Systems for Lactic CI2P 2 1/06 (2006.01) Acid Bacteria: Transferable Nisin-Inducible Expression Cassettes for Lactococcus, Leuconsostoc, and Lactobacillus spp. 63(11) (52) U.S. Cl. Applied and Environmental Microbiology 4581-4584 (1997).* CPC ...... CI2N 15/746 (2013.01); A61K 8/99 Reid et al., Potential Uses of Probiotics in Clinical Practice 16(4) (2013.01); A61 K35/744 (2013.01); A61O Clinical Microbiology Reviews 658-672 (2003).* 17/00 (2013.01); A61O 1704 (2013.01); A61O Gueniche et al., "Bifidobacterium longum lysate, a new ingredient for 19/007 (2013.01); A61O 19/08 (2013.01) reactive skin' 19 Experimental Dermatology el-e8 (2010).* (58) Field of Classification Search (Continued) None See application file for complete search history. Primary Examiner — Nancy J Leith (56) References Cited (74) Attorney, Agent, or Firm — Shay Glenn LLP U.S. PATENT DOCUMENTS (57) ABSTRACT 4,259,444 A 3/1981 Chakrabarty Compositions comprised of a population of transformed bac 5,620,682 A 4/1997 Fogel teria formulated for topical application to a Subject are 6,221,648 B1 4/2001 Le Page et al. described. The population of transformed bacteria are created 6,605,286 B2 8, 2003 Steidler et al. from a non-pathogenic bacteria and transformed to expr